

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10

**Complete If Known**

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1847
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005912US

U.S. PATENT DOCUMENTS					
Examiner	Cite No.	Document Number Number Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CS	340	2002/0162129 A1	10-31-2002	Lannfelt	_____
	326	2002/0136718 A1	09-26-2002	Raso	_____
	326	2001/0102261 A1	08-01-2002	Raso	_____
	306	6,417,178 B1	07-09-2002	Klunk et al.	_____
	342	2002/0009445 A1	01-24-2002	Du et al.	_____
	267	6,294,171 B2	09-25-2001	McMichael	_____
	234	6,284,221 B1	08-04-2001	Schenk, et al.	_____
	300	2001/0018053 A1	08-30-2001	McMichael	_____
	230	6,262,335 B1	07-17-2001	Hsiao et al.	_____
	345	2002/0077288 A1	06-21-2001	Frangione	_____
	231	6,114,133	09-05-2000	Seubert et al.	_____
	221	5,989,566	11-23-1999	Cobb et al.	_____
	283	09/441,140	11-16-1999	Solomon et al.	_____
	346	5,935,927	08-10-1999	Vitek et al.	_____
	321	5,837,872	11-17-1998	Schenk et al.	_____
	353	5,824,322	10-20-1998	Balasubramanian	_____
	357	5,776,468 B1	07-07-1998	Hauser et al.	_____
	358	5,822,701	04-22-1997	Berg	_____
	320	5,593,846	01-14-1997	Schenk et al.	_____
CS	358	5,583,112 B2	12-10-1996	Kensil et al.	_____
	284	5,231,170	07-27-1993	Averback	_____

U.S. PATENT DOCUMENTS					
Examiner	Cite No.	Document Number Number Kind Code <sup>3</sup> (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CS	286	60/254,466	12-08-2000	Holtzman et al.	_____
	287	60/254,486	12-08-2000	Holtzman et al.	_____
	285	00/724,942	11-28-2000	Chaffour et al.	_____
	286	60/184,804	08-24-2000	Holtzman et al.	_____
	282	60/160,687	12-08-1999	Chaffour	_____
	248	60/160,984	11-29-1999	Chaffour et al.	_____
CS	283	09/441,140	11-16-1999	Solomon et al.	_____
	288	60/160,286	03-01-2000	Rasmussen et al.	_____

Examiner  
Signature

C. Nichols

Date  
Considered

7/2/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
PA 3307311 v1

CONSIDERED; DO NOT PRINT.

MAY. 29. 2003 1:15PM

TTC-PA 650-326-2422

NO. 1212 P. 15/23

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

**Complete If Known**

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schank
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005912US

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
✓	351	WO	02/34878	A2	05-02-2002			
	352	WO	02/34777	A1	05-02-2002			
	343	EP	1 172 378	A1	01-16-2002			
	344	WO	01/90182	A2	11-29-2001			
	348	WO	01/77187	A2	10-18-2001			
	294	WO	01/62801	A2	08-30-2001			
	298	WO	01/42306	A2	08-14-2001			
	243	WO	01/39796	A2	06-07-2001			
	341	WO	02/03911	A2	04-07-2001			
	322	WO	00/72880	A2, A3	12-07-2000			
	323	WO	00/72876	A2, A3	12-07-2000			
	324	WO	00/72870	A1	12-07-2000			
	240	WO	00/43039	A1	07-27-2000			
	301	WO	01/62284	A2	03-01-2000			
✓	331	WO	99/06546	A2	11-02-1999			
✓	227	WO	95/11008	A2	04-27-1995			

Examiner  
Signature

C. Nichols

Date  
Considered

7/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
PA 33073111 v1

Received from &lt;650 326 2422&gt; at 5/29/03 4:13:52 PM (Eastern Daylight Time)

FTO/SB/048 (10-01)

Approved for use through 10/31/2002. OMB 0861-0331

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	Q15270-005812US
Sheet	3	of	10

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CSW	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 225(4): 1075-1093 (1992).	
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:58 PM ET.	
	327	CAMERON, "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> , 7:263-286 (1997).	
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992).	
	<del>254</del>	<del>Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), website contents found at: <a href="http://www.fda.gov/cber/vaccine/thimerosal.htm">http://www.fda.gov/cber/vaccine/thimerosal.htm</a>, last updated May 16, 2002.</del>	
	266	CHAPMAN, PAUL F., "Model behavior," <i>Nature</i> , 408:915-916 (2000).	
	222	<del>Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologics," Chemical Abstract database. (Publication date unknown.)</del>	
	932	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V-F transgenic mice," <i>Progress in Brain Research</i> , Van Leeuwen et al. Eds, 117:327-337 (1998).	
	307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease." <i>Nature</i> , 408(6815):975-9 (2000).	
	302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid $\beta$ -Peptide by Microglial Cells," <i>J. Biol. Chem.</i> , 274(45):32301-32308 (1999).	
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <i>Pharm. Res.</i> , 17:266-274 (2000).	
CSW	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy." <i>PNAS</i> , 97(2):671-676 (2000)	
Examiner Signature	<i>[Signature]</i>		Date Considered 7/22/03

\* EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307311 v1

CONSIDERED; DO NOT PRINT.

MAY. 29. 2003 1:16PM

TTC-PA 650-326-2422

NO. 1212 P. 17/23

PTO/SB/015 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		An Unit	1647
		Examiner Name	Christopher J. Nichols
Sheet 4 of 10	Attorney Docket Number	015270-005912US	

286	CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).
293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).
220	Biolog Berwint, Abstract of WPI Abs NO: 1997-054436/199706: Stable vaccine compounds - comprise a macrocyclic lactone, a milbemycin, an aversin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water, Berwint File 301- Berwint WPI database. (Publication date unknown.)
318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. <u>Neurology</u> , 57(5):801-5 (2001).
288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).
226	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).
328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing," <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999).
247	FRENKEL et al., "Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).

CONSIDERED; DO NOT PRINT.

Examiner Signature	<i>G. Nichols</i>	Date Considered	7/2/03
--------------------	-------------------	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307311 v1

Received from &lt; 650 326 2422 &gt; at 5/29/03 4:13:52 PM [Eastern Daylight Time]

PTO/SB/05B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

**Complete if Known**

Application Number	08/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1847
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005912US

248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's $\beta$ -amyloid peptide represents the epitope of its anti-aggregating antibodies," <i>J. of Neuroimmunology</i> , 88:85-90 (1998).
244	FRENKEL, et al., "Modulation of Alzheimer's $\beta$ -amyloid neurotoxicity by site-directed single chain antibody," <i>J. of Neuroimmunology</i> , 106:23-31 (2000).
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <i>Cerebrovascular Pathology in Alzheimer's Disease</i> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <i>Biochem. Biophys. Res. Comm.</i> , 173:1292-1298 (1990).
252	GEDDES, "N-terminus truncated $\beta$ -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <i>Neurobiology of Aging</i> , 20:75-79 (1999).
253	GIULIAN, et al., "The HHQK Domain of $\beta$ -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>Journal of Biological Chem.</i> , 273:29719-29726 (1998).
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 83:149-153 (1998).
237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?", <i>TINS</i> , 23:114 (2000).
241	HAASS et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-6 (1992).
255	HARIGAYA, et al., "Modified amyloid $\beta$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 211:1015-1022 (1995).
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <i>Immunology</i> , Vol. 78: 643-649 (1993).
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).

Examiner  
Signature

Date

Considered

7/21/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307311 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1847
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	015270-005912US
Sheet	6	of	10

256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- $\beta$ protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).
308	JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. <u>Nature</u> , 408(6815):979-82 (2000).
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).
334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991).
347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , May:497-502 (1981).
258	KIDA, et al., "Early amyloid- $\beta$ deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997).
260	LEMERE, et al., "Nasal A $\beta$ treatment induces anti-A $\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).
263	MANN, et al., "Amyloid $\beta$ protein (A $\beta$ ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A $\beta$ <sub>42</sub> ," <u>Annals of Neurology</u> , 40:149-158 (1996).
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 198:105-108 (1995).
335	MASLIAH et al., " $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).
309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol. Rev.</u> 77(4):1081-132 (1997).

Examiner Signature	<i>G. Wiles</i>	Date Considered	7/22/03
--------------------	-----------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3307311 v1

MAY. 29. 2003 1:17PM

TTC-PA 650-326-2422

NO. 1212 P. 20/23

PTO/SB/02B (10-01)

Approved for use through 10/31/2002. OMB 0681-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 10

**Compl to Known**

Application Number	08/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher J. Nichols
Attorney Docket Number	015270-005912US

264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <i>J. of Neuroscience Res.</i> , 31:428-442 (1992).	
238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:168-186 (1998).	
265	MENA, et al., "Monitoring pathological assembly of tau and $\beta$ -amyloid proteins in Alzheimer's disease," <i>Acta Neuropathol.</i> , 89:50-56 (1995).	
310	MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. <i>Adv Clin Path.</i> 4(2):77-85 (2000).	
311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <i>Nature</i> , 408(6815):982-5 (2000).	
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <i>Neurology</i> , 39:1159-65 (1989).	
359	MUNCH et al., "Potential neurotoxic inflammatory response to A $\beta$ vaccination in humans," (2002) <i>J. Neural Transm.</i> , 109:1081-1087.	
355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1996), 47-48, Chapman & Hall, New York, New York.	
354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1996) 7, 11-12, <i>medpharm Scientific Publishers</i> , Stuttgart, Germany.	
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <i>Exp. Anim.</i> , 43:711-718 (1995).	
208	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid $\beta$ protein (A $\beta$ ) subtypes (A $\beta$ 40 and A $\beta$ 42/43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <i>Neuroscience Letters</i> , 201:151-154 (1995).	
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <i>J. of Med. Primatology</i> , 27:244-252 (1998).	
235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <i>Biochim. Biophys. Acta</i> , 104:480-488 (1965).	
329	NIEMANN, "Transgenic farm animals get off the ground," <i>Transgenic Research</i> 7:73-75 (1998).	

Examiner  
SignatureDate  
Considered

7/22/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307311 v1

Received from &lt;650 326 2422&gt; at 5/29/03 4:13:52 PM [Eastern Daylight Time]

PTO/SB/018 (10-01)

Approved for use through 10/31/2002. OMB 0861-0021  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dele B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	015270-005912US
Sheet	8	of	10

280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 148:307-313 (1987).
336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).
269	PHILIPPE, et al., "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).
<del>664</del>	<del>RASO, V.A., Grant application # 1 R43 AG1-6746-04 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).</del>
279	SAITO et al., "Vector-mediated delivery of <sup>125</sup> I-labeled $\beta$ -amyloid peptide Ab <sup>1-40</sup> through the blood-brain barrier and binding to Alzheimer disease amyloid of the Ap <sup>1-40</sup> vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).
278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- $\beta$ -protein monoclonal antibodies," <u>Sepporo Med. J.</u> , 60:309-320 (1991).
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).
312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. <u>DNA Cell Biol.</u> 20(11):678-81 (2001).
270	SCHENK, et al., " $\beta$ -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).
313	SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. <u>Trends Cell Biol.</u> 8(11):447-53 (1998).
330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1426-1429 (2000).
314	SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. <u>J Neuropathol Exp Neurol.</u> 59(1):11-17 (2000).
315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. <u>Ann N Y Acad Sci.</u> 920:206-8 (2000).

CONSIDERED; DO NOT PRINT.

Examiner Signature	<i>g. nichols</i>	Date Considered	7/22/03
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3307311 v1



PTO/SB/68B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	08/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	015270-005912US
Sheet	9	of	10

337	SKOLNICK and FEYROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39 (2000).
319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <i>Nat Rev Neurosci.</i> 2(8):596-8 (2001).
316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. <i>Nat Med.</i> 4(7):822-6 (1998).
271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <i>Nature</i> , 40:116-117 (1998).
338	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transferrin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002).
272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid $\beta$ -peptide as modeled with N-terminal decapeptide fragments," <i>Int. J. Peptide Protein Res.</i> 47:289-296 (1996).
339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4289-4303 (1995).
273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000).
276	TJERNBERG et al., "Arrest of $\beta$ -amyloid fibril formation by a pentapeptide ligand," <i>Journal of Biological Chemistry</i> , 271:8545-8548 (1996).
317	VEHWAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <i>ONA Cell Biol.</i> (11):713-21 (2001).
274	WEINER et al., "Nasal administration of amyloid- $\beta$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 48:567-579 (2000).
<del>229</del>	<del>WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven-Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 76(24), 56. (Publication date unknown.)</del>
275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997).

CONSIDERED; DO NOT PRINT.

Examiner Signature		Date Considered	7/22/03
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307311 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
		Attorney Docket Number	015270-005912US
Sheet	10	of	10

	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid $\beta$ protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).	
	290	YOUNKIN, "Amyloid $\beta$ vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).	

Examiner Signature		Date Considered	7/22/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3307311 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005912US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESD	349	CLARK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	—
ESD	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	—

RECEIVED

MAY 30 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	7/14/03
-----------------------	--	--------------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PA 3306916 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete If Known

Application Number 09/724,575  
Filing Date November 28, 2000  
First Named Inventor Dale B. Schenk et al.  
Group Art Unit 1632 K44  
Examiner Name Not Yet Assigned Nichols  
Attorney Docket Number 15270J-005912US



## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CS	196	6,150,091		Pandolfo et al.	11-21-2000	
CS	1	6,057,367		Stamler et al.	05-02-2000	
CS	2	5,958,883		Snow	09-28-1999	
CS	3	5,955,317		Suzuki et al.	09-21-1999	
CS	4	5,955,079		Mond et al.	09-21-1999	
CS	5	5,877,399		Hsiao et al.	03-02-1999	
CS	6	5,869,093		Weiner et al.	02-09-1999	
CS	7	5,869,054		Weiner et al.	02-09-1999	
CS	8	5,854,204		Findeis et al.	12-29-1998	
CS	9	5,851,986		Kline	12-22-1998	
CS	10	5,849,298		Weiner et al.	12-15-1998	
CS	11	5,837,473		Maggio et al.	11-17-1998	
CS	12	5,786,180		Konig et al.	07-28-1998	
CS	207	5,780,587		Potter	07-14-1998	
CS	13	5,753,624		McMichael et al.	05-19-1998	
CS	14	5,750,349		Suzuki et al.	05-12-1998	
CS	197	5,744,368		Goldgaber et al.	04-28-1998	
CS	211	5,736,142		Sette et al.	04-07-1998	
CS	15	5,733,547		Weiner et al.	03-31-1998	
CS	16	5,688,651		Solomon	11-18-1997	
CS	17	5,679,348		Nesburn et al.	10-21-1997	
CS	18	5,645,820		Hafler et al.	07-08-1997	
CS	19	5,641,474		Hafler et al.	08-24-1997	
CS	20	5,641,473		Hafler et al.	08-24-1997	
CS	21	5,612,486		McConlogue et al.	03-18-1997	
CS	22	5,605,811		Seubert et al.	02-25-1997	
CS	23	5,585,100		Mond et al.	12-17-1996	
CS	24	5,571,500		Hafler et al.	11-05-1996	
CS	25	5,571,499		Hafler et al.	11-05-1996	
CS	175	5,441,870		Seubert, et al.	08-15-1995	
CS	26	5,434,170		Andrulis, Jr.	07-18-1995	
CS	27	5,387,742		Cordell	02-07-1995	
CS	181	5,270,165		Van Nostrand et al.	12-14-1993	
CS	28	5,231,000		Majocha et al.	07-27-1993	
CS	29	5,220,013		Ponte et al.	08-15-1993	
CS	30	5,208,036		Eppstein et al.	05-04-1993	
CS	31	5,192,753		McGeer et al.	03-09-1993	

Examiner Signature *[Signature]* Date Considered 11/15/02

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	4632 1617
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US



32	5,187,153	Cordell et al.	02-18-93
33	5,057,540	Kensil et al.	10-15-1991
198	5,004,697	Pardridge	04-0201991
34	4,666,829	Glennier et al.	05-19-1987

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
32	35	EP	911 036	A2		04-28-1999		
33	36	EP	868 918	A2		10-07-1998		
34	37	EP	883 211	A1		09-09-1998		
35	38	EP	845 270	A1		06-03-1998		
36	39	EP	782 859	A1		07-09-1997		
37	40	EP	683 234	A1		11-22-1995		
38	41	EP	666 080	A1		08-08-1995		
39	42	EP	652 982	B1		12-16-1998		
40	43	EP	639 081	B1		11-03-1999		
41	44	EP	613 007	A2		08-31-1994		
42	45	EP	594 607	B1		08-27-1997		
43	46	EP	561 087	B1		08-04-1999		
44	47	EP	526 511	B1		05-28-1997		
45	48	EP	506 785	B1		03-15-2000		
46	49	EP	451 700	A1		10-16-1991		
47	50	EP	440 619	B1		01-24-1998		
48	51	EP	358 783	B1		11-29-1995		
49	52	EP	276 723	B1		12-08-1993		Yes
50	187	EP	792 104	A1		07-08-1997		
51	188	PCT	00/77178	A1		12-21-2000		
52	189	PCT	00/43049	A1		07-27-2000		
53	53	PCT	99/60024	A1		11-25-1999		
54	54	PCT	99/60021	A2		11-15-1999		
55	55	PCT	99/58564	A1		11-18-1999		
56	56	PCT	99/08066	A2		02-11-1999		
57	57	PCT	99/27949	A1		06-10-1999		
58	58	PCT	99/27944	A1		08-10-1999		
59	59	PCT	99/27911	A1		06-10-1999		
60	203	PCT	99/00150	A2		01-07-1999		
61	60	PCT	98/44955	A1		10-15-1998		
62	61	PCT	98/07850	A2		02-26-1998		

Examiner Signature	<i>G. M. S.</i>	Date Considered	11/15/02
--------------------	-----------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number 09/724,575  
Filing Date November 28, 2000  
First Named Inventor Dale B. Schenk et al.  
Group Art Unit 1632-4647  
Examiner Name Not Yet Assigned Nicholas  
Attorney Docket Number 15270J-005912US



202	PCT	97/21728	A1	06-19-1997
62	PCT	97/17613	A1	05-15-1997
63	PCT	96/39176	A1	12-12-1996
208	PCT	96/28471	A1	09-19-1996
64	PCT	96/25435	A1	08-22-1996
65	PCT	96/18900	A1	08-20-1996
66	PCT	95/31996	A1	11-30-1995
200	PCT	95/12815	A1	05-11-1995
67	PCT	95/11994	A1	05-04-1995
68	PCT	95/11311	A1	04-27-1995
69	PCT	95/05853	A1	03-02-1995
70	PCT	95/04151	A2	02-09-1995
201	PCT	94/28412	A1	12-08-1994
71	PCT	94/03615	A1	02-17-1994
72	PCT	94/01772	A1	01-20-1994
73	PCT	93/21950	A1	11-11-1993
74	PCT	93/16724	A1	09-02-1993
75	PCT	93/15760	A1	08-19-1993
76	PCT	93/14200	A1	07-22-1993
205	PCT	93/04194	A1	03-04-1993
77	PCT	93/02189	A1	02-04-1993
78	PCT	92/13089	A1	08-06-1992
79	PCT	92/06708	A1	04-30-1992
80	PCT	92/06187	A1	04-16-1992
81	PCT	91/19810	A1	12-26-1991
82	PCT	91/16819	A1	11-14-1991
83	PCT	91/12816	A1	09-05-1991
84	PCT	91/08760	A1	06-27-1991
85	PCT	90/12871	A1	11-01-1990
86	PCT	90/12870	A1	11-01-1990
87	PCT	89/01343	A1	02-23-1989
88	PCT	89/06242	A1	07-13-1989
89	PCT	89/06689	A1	07-27-1989
90	PCT	88/03687	A1	05-05-1989
91	PCT	88/10120	A1	12-29-1988
92	GB	2 220 211	A	01-04-1990
93	GB	2 335 192	A	09-15-1999

Examiner Signature *[Signature]* Date Considered 11/5/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1


Please type a plus sign (+) inside this box → +

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/724,575</td> </tr> <tr> <td>Filing Date</td> <td>November 28, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>Dale B. Schenk et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1692- Not</td> </tr> <tr> <td>Examiner Name</td> <td>Not Yet Assigned Nichols</td> </tr> <tr> <td>Attorney Docket Number</td> <td>15270J-005912US</td> </tr> </table>		Application Number	09/724,575	Filing Date	November 28, 2000	First Named Inventor	Dale B. Schenk et al.	Group Art Unit	1692- Not	Examiner Name	Not Yet Assigned Nichols	Attorney Docket Number	15270J-005912US
Application Number	09/724,575														
Filing Date	November 28, 2000														
First Named Inventor	Dale B. Schenk et al.														
Group Art Unit	1692- Not														
Examiner Name	Not Yet Assigned Nichols														
Attorney Docket Number	15270J-005912US														
Sheet	4	of	10												



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CSO	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <i>Neurology</i> , 45:1441-1445 (1995).	<input type="checkbox"/>
CSO	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95).	<input type="checkbox"/>
CSO	96	BAUER et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991).	<input type="checkbox"/>
GNW	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> , 29:345-354 (1999).	<input type="checkbox"/>
GNW	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:764 (1992).	<input type="checkbox"/>
GNW	176	BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000).	<input type="checkbox"/>
CSO	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input type="checkbox"/>
CSO	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input type="checkbox"/>
CSO	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997).	<input type="checkbox"/>
GNW	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Cur. Opin. Genet. Develop.</i> , 3: 102-109 (1993).	<input type="checkbox"/>
GNW	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 56:112-115 (1993).	<input type="checkbox"/>
GNW	102	CHAO et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513.7 (1993).	<input type="checkbox"/>
GNW	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <i>Neuroscience Letters</i> 125:223-226 (1991).	<input type="checkbox"/>
GNW	214	DEMATOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 10, 1073/pnas.151261398 (2001).	<input type="checkbox"/>
GNW	103	DUFF et al., "Mouse model made," <i>Nature</i> , 373: 476-477 (1995).	<input type="checkbox"/>

Examiner Signature		Date Considered	11/15/02
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not chosen is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 10

## Complete If Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 R47
Examiner Name	Not Yet Assigned Nichols
Attorney Docket Number	15270J-005912US



104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).
105	FELSENSTEIN et al., "Processing of the $\beta$ -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).
108	FLANDERS et al., "Altered expression of transforming growth factor- $\beta$ in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).
210	FRIEDLAND et al., "Development of an anti-A $\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A $\beta$ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 685-690 (1984).
114	GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).
190	GRAVINA et al., "Amyloid $\beta$ Protein (A $\beta$ ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).
118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).

Examiner Signature	<i>[Signature]</i>	Date Considered	11/15/02
--------------------	--------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known

Application Number 09/724,575  
Filing Date November 28, 2000  
First Named Inventor Dale B. Schenk et al.  
Group Art Unit 1632-1647  
Examiner Name Not Yet Assigned Nichols  
Attorney Docket Number 15270J-005912US



119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	—
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	—
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	—
193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ /A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	—
177	HELMUTH, L., "Further Progress on a $\beta$ -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	—
122	HSIAO et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 89-102 (1996).	—
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	—
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	—
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	—
192	IWATSUBO et al., "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in Senile Plaques with End-Specific A $\beta$ Monoclonals: Evidence That an Initially Deposited Species Is A $\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).	—
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	—
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-378 (1991).	—
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	—
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	—
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	—
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the $\beta$ A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	—
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	—
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	—

Examiner Signature G. M. [Signature] Date Considered 11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 10

Complete If Known

Application Number 09/724,575  
Filing Date November 28, 2000  
First Named Inventor Dale B. Schenk et al.  
Group Art Unit 4692-1647  
Examiner Name Not Yet Assigned Nicholas  
Attorney Docket Number 15270J-005912US



131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).	
132	LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part 1, Abstract 519.6, 28th Annual Meeting, (October 23-28, 1999).	
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).	
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).	
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).	
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 187-210 (1997).	
136	MEDA et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," <u>Nature</u> , 374:647-650 (1995).	
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).	
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).	
141	PAUL et al., "Transdermal immunization with large proteins by means of ultra-deformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).	
143	QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	
144	<del>PAGE, V.A., Grant application # 1-P48-A215748-01 (publication date unknown)</del>	

Examiner Signature	<i>G. Miao</i>	Date Considered	11/15/02
--------------------	----------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3189626 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

## Complete if Known

Application Number	09/724,575
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk et al.
Group Art Unit	1632 KAT
Examiner Name	Not Yet Assigned
Attorney Docket Number	15270J-005912US



gn	145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	—
gn	146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	—
gn	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	—
gn	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1978).	—
gn	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	—
gn	194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	—
gn	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	—
gn	148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	—
gn	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	—
gn	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	—
gn	151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	—
gn	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	—
gn	153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	—
gn	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	—
gn	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	—
gn	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	—
gn	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	—
gn	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	—

Examiner Signature		Date Considered	11/15/02
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box.

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

## Complete If Known

Application Number 09/724,575  
Filing Date November 28, 2000  
First Named Inventor Dale B. Schenk et al.  
Group Art Unit 4882 1647  
Examiner Name Not Yet Assigned Nichols  
Attorney Docket Number 15270J-005912US



SW	159	SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	
SW	160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	
SW	161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	
	162	<del>SOLOMON, B., "New Approach Towards Fast Induction of Anti <math>\beta</math>-Amyloid Peptide Immune Response," Department of Molecular Microbiology &amp; Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown).</del>	
SW	182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	
SW	184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	
SW	185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	
	186	<del>SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).</del>	
SW	179	SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	
SW	163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).	
SW	164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	
SW	165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).	
SW	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	
SW	167	VAN GOOL et al., "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).	
SW	168	VERBEEK et al., "Accumulation of Interleukin Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	
SW	169	WALKER et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	
SW	180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	
SW	170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).	

Examiner  
Signature

*G. Miller*

Date

Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3189626 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk et al.
		Group Art Unit	1632-1647
		Examiner Name	Not Yet Assigned - Nichols
Sheet 10 of 10	Attorney Docket Number	15270J-005912US	

O I P E  
DEC 11 2001  
INFORMATION OFFICE

GW	171	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	—
GW	172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-874 (2000).	—
GW	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).	—
GW	173	WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).	—
	174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	—

Examiner Signature	<i>G. M. [Signature]</i>	Date Considered	11/15/02
--------------------	--------------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3189626 v1